NCT05976217View on ClinicalTrials.gov

Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

March 18, 2024

Study Completion Date

March 20, 2024

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Venetoclax

100 mg daily by mouth for 3 weeks This drug inhibits a protein (Bcl-2) that protects cells from undergoing programmed cell death.

Trial Locations (2)

35214

TKC, Birmingham

35233

UAB, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT05976217 - Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter